Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab-Reference-Cited by-同舟云学术

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Published:2017-10 Issue:10 Volume:15 Page:1580-1588.e3
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Papamichael Konstantinos,Chachu Karen A.,Vajravelu Ravy K.^ORCID,Vaughn Byron P.,Ni Josephine,Osterman Mark T.,Cheifetz Adam S.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference27 articles.

1. Comparative effectiveness of infliximab and adalimumab for Crohn's disease;Osterman;Clin Gastroenterol Hepatol,2014

2. Loss of response to anti-TNF treatments in Crohn's disease;Ben-Horin;Aliment Pharmacol Ther,2011

3. Use of anti-TNF drug concentrations to optimise patient management;Papamichael;Frontline Gastroenterol,2016

4. Biologic concentration testing in inflammatory bowel disease;Vaughn;Inflamm Bowel Dis,2015

5. Impact of antibodies to infliximab on clinical outcomes and serum infliximab concentrations in patients with inflammatory bowel disease (IBD): a meta-analysis;Nanda;Am J Gastroenterol,2013

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. Ischemic heart disease mortality in individuals with inflammatory bowel disease: A nationwide analysis of disparities in the United States;Cardiovascular Revascularization Medicine;2024-08

3. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease;Journal of Pediatric Gastroenterology and Nutrition;2024-07-09

4. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab;Inflammatory Bowel Diseases;2024-07-02

5. The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study;Pediatric Discovery;2024-06-25